Cefprozil Tablet, Film Coated
Product Images NDC 16714-398

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Cefprozil (NDC 16714-398). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label-principal Display Panel (250 mg (100 Tablet Bottle))

Package Label-principal Display Panel (250 mg (100 Tablet Bottle))
This is a description of Cefprozil Tablets, USP, a prescription drug containing 250 mg of Cefprozil. It is packaged in a container and needs to be kept in a cool, dry place out of reach for children. The usual Dosage of the drug is found in the package insert. This drug is manufactured in India and distributed by Northstar Rx LLC from their facility in Memphis, TN. The NDC number for these tablets is 16714-398-01.*
FDA Label Image

Package Label-principal Display Panel (500 mg (50 Tablet Bottle))

Package Label-principal Display Panel (500 mg (50 Tablet Bottle))
The text describes a medication with the NDC 16714-399-01 containing 50 tablets of 500 mg of Cefprozil. Each tablet has a film coating and should be dispensed in a tight light-resistant container. The usual dosage information is included in a package insert for Dosage and Administration. The medication should be stored between 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The medication is manufactured by Aurobindo Pharma Limited in Chitkul (V)-502 307, India for Northstar Rx LLC in Memphis, TN 38141.*
FDA Label Image

Chemical Structure (Cefprozil Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.